Redeye makes slight adjustments to the near-term estimates. The long-term outlook for MOB-15 still looks bright, and the slightly increased Base case remains significantly above the current share price. We see that Moberg Pharma is progressing as planned, and the submittal of the registration application in the H2 of 2021 should be an important catalyst as we advance.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/